Last reviewed · How we verify

NCT04321668: RESYF

Innovative Tool to Analyse Synovial Fluid of Patients With Knee Ostearthritis After IA Injection of Synvisc-one®

Completed NA Last updated 22 April 2022
What this trial tests

NA trial testing Synvisc-One in Knee Osteoarthritis in 13 participants. Completed in 15 February 2022.

Timeline
12 February 2020
Primary endpoint
1 October 2021
15 February 2022

Quick facts

Lead sponsorPulsalys
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposesupportive care
Enrollment13
Start date12 February 2020
Primary completion1 October 2021
Estimated completion15 February 2022
Sites3 locations across Belgium

Drugs / interventions tested

Conditions studied

Sponsor

Pulsalys

Who can join

Adults 40 to 80, any sex, with Knee Osteoarthritis or Intra-Articular Injection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this trial is to assess the clinical pertinence of an innovative analytical tool (SYNODIAG) to analyze the Synovial Fluid (SF) composition and guide the patient treatment in a Proof of Concept (PoC) study using OA patients receiving IA injection of SYNVISC ONE®.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Synvisc-One

Trials testing the same drug.

Other recruiting trials for Knee Osteoarthritis

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04321668.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing